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Abstract
Summary This study in 8 countries across Europe found that about 75% of elderly women seen in primary care who were at high
risk of osteoporosis-related fractures were not receiving appropriate medication. Lack of osteoporosis diagnosis appeared to be an
important contributing factor.
Introduction Treatment rates in osteoporosis are documented to be low. We wished to assess the osteoporosis treatment gap in
women ≥ 70 years in routine primary care across Europe.
Methods This cross-sectional observational study in 8 European countries collected data from women 70 years or older visiting
their general practitioner. The primary outcome was treatment gap: the proportion who were not receiving any osteoporosis
medication among those at increased risk of fragility fracture (using history of fracture, 10-year probability of fracture above
country-specific Fracture Risk Assessment Tool [FRAX] thresholds, T-score ≤ − 2.5).
Results Median 10-year probability of fracture (without bone mineral density [BMD]) for the 3798 enrolled patients was 7.2%
(hip) and 16.6% (major osteoporotic). Overall, 2077 women (55%) met one or more definitions for increased risk of fragility
fracture: 1200 had a prior fracture, 1814 exceeded the FRAX threshold, and 318 had a T-score ≤ − 2.5 (only 944 received a dual-
energy x-ray absorptiometry [DXA] scan). In those at increased fracture risk, the median 10-year probability of hip and major
osteoporotic fracture was 11.2% and 22.8%, vs 4.1% and 11.5% in those deemed not at risk. An osteoporosis diagnosis was
recorded in 804 patients (21.2%); most (79.7%) of these were at increased fracture risk. The treatment gap was 74.6%, varying
from 53% in Ireland to 91% in Germany. Patients with an osteoporosis diagnosis were found to have a lower treatment gap than
those without a diagnosis, with an absolute reduction of 63%.
Conclusions There is a large treatment gap in women aged ≥ 70 years at increased risk of fragility fracture in routine primary care
across Europe. The gap appears to be related to a low rate of osteoporosis diagnosis.
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Introduction
Over 8.9 million osteoporotic or fragility fractures occur every
year across the globe, more than a third of which occur in
Europe [1, 2]. In 2010, 3.5 million new fragility fractures
(FFs) in 22 million women aged over 50 were estimated to
have occurred across the EU; and FFs are predicted to increase
due to changing demographics [3]. It has been suggested that
approximately 51% of the hip fractures that occur globally are
potentially preventable [4]. Hence, disease awareness, early
diagnosis, prevention, and appropriate treatment of fractures
are critical in osteoporosis (OP) management. However, the
diagnosis of OP frequently occurs only after a fracture, and
even then treatment rates can be low [4].
General practitioners (GPs) play a critical role in OP man-
agement. To begin with, they are well positioned to assess risk
factors in the general population [5]. For example, in a cross-
sectional survey on women 45 years or older in the French
general population, the diagnosis of OP was most commonly
made by a GP (approximately 45% of diagnoses [6]); and in a
single OP clinic in the UK, 94% of the referrals for bone
mineral density (BMD) scans over the course of 1 year had
been made by GPs [7]. For patients who experience OP-
related fractures, a cost burden is also placed on primary care.
A study of UK databases reported that primary care costs
increased significantly in the first 2 years after hip fracture
[8]. Coordinator-based fracture liaison services for secondary
prevention also usually require the GP’s involvement as part
of a multi-disciplinary team for treating patients and monitor-
ing their progress [9, 10].
Diagnostic methods and fracture risk assessment have im-
proved in recent years. However, despite new interventions to
reduce fracture risk and new clinical practice guidelines, only
a small fraction of eligible women receive treatment for OP,
implying a high treatment gap [11]. It was estimated that 10.6
out of the 18.4 million women in the EU who exceeded the
threshold risk for FF were not treated, representing a treatment
gap of 57% [3]. This is likely to be an underestimate, as the
analysis assumed that all OP drug usage was targeted appro-
priately at individuals at high risk. In the absence of recent
real-world data, we designed this study to specifically focus
on assessing the treatment gap in a large sample of women ≥
70 years in Europe who were routinely visiting their GPs.
Methods
Study design
This cross-sectional, multicenter, multi-country observational
study included 153 GP sites across 8 countries: Belgium,
France, Germany, Ireland, Poland, Slovakia, Switzerland,
and the UK. Countries were included based on regulatory
requirements and feasibility. GP offices were selected based
on interest in participation as a study site, and willingness and
ability to comply with the protocol and data entry conven-
tions. Community-dwelling women 70 years or older who
spontaneously visited their GP were invited to participate,
and, following informed consent, completed a short self-
reported questionnaire.
The primary objective was to assess the proportion of
women ≥ 70 years who were at increased risk of FF (see
following) and not receiving any OP medication. Increased
risk of FF was defined by the presence of at least one of the
following three base criteria:
1. History of fracture after the age of 50 (hip, spine, wrist, or
other OP-related fractures)
2. Increased 10-year probability of both hip and major oste-
oporotic fracture (calculated using Fracture Risk
Assessment Tool [FRAX] without BMD above country-
specific threshold (Table S1), using an approach similar to
that recommended by the National Osteoporosis
Guidance Group, UK [9])
3. BMD T-score ≤ − 2.5 for lumbar spine, total hip, or fem-
oral neck.
Key secondary objectives included the description of pa-
tient characteristics among those at increased risk of FF or not,
and a description of the types of OP medications used.
Specific osteoporosis medications were assessed in the
overall population, according to fracture history and according
to current or previous use (within the last 10 years). Line of
treatment was assessed among current users: no previously
documented osteoporosis treatment indicated first-line use,
and one type of previous osteoporosis medication indicated
second-line use.
Sensitivity analyses were conducted using alternative def-
initions of increased risk of FF based on FRAXwithout BMD
(criterion 2) and involved increasing or decreasing the major
osteoporotic fracture and hip fracture thresholds by absolute
values of 5% and 2%, respectively. A further analysis exam-
ined the same threshold as in the primary analysis, but with the
FRAX probabilities calculated with the inclusion of BMD,
where available.
Data collection
The following variables were collected from the patient’s
existing medical records: demographics (age, gender, coun-
try); weight; height; body mass index (BMI); reason for con-
sultation; smoking status; alcohol consumption; parental his-
tory of hip fracture; fracture history; falls in the past year; any
known OP diagnosis; BMD results from last dual-energy x-
ray absorptiometry (DXA) scan, if available; use of glucocor-
ticoids; comorbidities (rheumatoid arthritis [RA], diabetes,
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hypertension, osteoarthritis, and chronic obstructive pulmo-
nary disease [COPD]) and associated treatments; OP medica-
tions used within the last 10 years (selective estrogen receptor
modulators [SERMs], oral bisphosphonates [BPs], parenteral
BPs, strontium ranelate, parathyroid hormone [PTH], anti-
receptor activator of nuclear factor kappa-Β ligand [anti-
RANKL]/denosumab; use of vi tamin D/calc ium
supplements).
Questionnaires were administered at the patient’s single
GP visit, which asked for information on the patient’s age,
height, weight, alcohol intake, parental hip fracture, history
of fracture after age 50, and falls in the last year. Where there
were discrepancies between medical records and the question-
naires, data from medical records were used.
Study size
No formal hypothesis was tested. A sample size of 4000 (500/
country) was expected to estimate the primary outcome for
each participating country with sufficient precision, assuming
that 40% of women ≥ 70 years of age would be at increased
risk of fracture and at least 50% of these would not be receiv-
ing an OP medication.
Statistical analysis
All analyses were descriptive. No statistical inference or im-
putations of missing data were planned. Analyses of the pri-
mary outcome were based on the primary analysis subset, i.e.,
all enrolled patients who were at increased risk of FF. Where
applicable, secondary analyses were done on the full analysis
set (FAS), consisting of all enrolled patients. Sensitivity anal-
yses of the primary and key secondary outcomes were per-
formed using different definitions of increased risk of FF (de-
scribed earlier).
Results
Description of overall study population
Data were collected between 28 March 2018 and 26 October
2018. A total of 3798 patients (median age, 77 years) were
enrolled. In each country, approximately 500 patients were
enrolled across 18 to 25 sites (Table 1), except for
Switzerland (n = 205 across 6 sites). The largest number was
enrolled in France (n = 543). The most common reason for
consultation was “follow-up to known disease” (52.1%),
followed by “new symptoms/complaints” (21.7%), “medica-
tion refill” (20.6%), and “other” (5.6%). The median 10-year
probability of hip fracture was 7.2%, and of major osteopo-
rotic fracture, 16.6% (both calculated without BMD; Table 1).
Patient recruitment and classification by fracture risk, OP
diagnosis, and whether treated with OP medication or not are
shown in Fig. 1. Of all the enrolled patients, 2077 (55%) were
deemed to be at increased risk of FF using the base criteria for
fracture risk. Of the total population, 804 patients (21.2%) had
an OP diagnosis identified in their medical records, and the
majority of these (641, 79.7%) were in the increased fracture
risk group. Importantly, BMD results were available in 944
women only (24.9% of the cohort), with BMD results for
lumbar spine available in 908 women (23.9% of the whole
cohort), for the total hip in 747 women (19.6% of the whole
cohort), and for the femoral neck in 727 (19.1% of the whole
cohort). Thus, the number classified at high risk based on
BMD (T-score ≤ 2.5) was derived from a smaller subset of
the cohort.
Prevalence of increased fracture risk and treatment
gap
Those at increased risk of FF were older than those not at
increased risk (median 80.0 years vs. 75.0 years; Table 2).
They also had a lower median BMI and, as expected, a higher
prevalence of risk factors associated with increased fracture
risk apart from current smoking and alcohol exposure.
Overall, 3361 patients (88.5%) reported at least one comor-
bidity, with similar proportions in patients with and without
Table 1 Overall patient characteristics
Parameter Descriptive statistics









Age, median (Q1, Q3), years 77.0 (73.0, 82.0)
BMI, median (Q1, Q3), kg/m2 26.9 (23.9, 30.5)
Known OP diagnosis, n (%) 804 (21.2)
Reason for consultation, n (%)
Follow-up to known disease 1978 (52.1)
Medication refill 782 (20.6)
New symptoms/complaints 824 (21.7)
Other 214 (5.6)
10-year fracture probability without BMD, median (Q1, Q3), %
Hip fracture 7.2 (4.1, 11.9)
Major osteoporotic fracture 16.6 (11.5, 23.9)
BMD, bone mineral density; BMI, bodymass index;OP, osteoporosis;Q,
quartile
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increased risk of FF. The most common comorbidities overall
were hypertension (2840, 74.8%), osteoarthritis (1702,
44.8%), and diabetes (953, 25.1%; data not shown). The me-
dian FRAX 10-year probabilities of a major osteoporotic frac-
ture and hip fracture (calculated without BMD)were 1.98-fold
and 2.73-fold higher, respectively, than those not an increased
risk (22.8 vs. 11.5 and 11.2 vs. 4.1, respectively).
For the primary outcome of treatment gap in patients at
increased risk of FF, 1550 (74.6%) were not receiving OP
medication (Fig. 2). Across countries, the treatment gap varied
from 53% in Ireland to 91% in Germany (Online Resource
Figure S1).
The treatment gap was notably different depending on
whether a diagnosis of OPwas recorded. Thus, in womenwith
increased risk and a diagnosis of OP, the treatment gap was
only 30.9%, while in those with increased risk and no OP
diagnosis, the gap was 94.1%. A diagnosis was therefore as-
sociated with an absolute reduction in treatment gap of 63%
(Fig. 2). An ad hoc analysis of the subset of patients who
received a DXA scan showed that 54% (508/944) were not
treated; and an analysis of the subset of patients who had a
recorded T-score showed that 21% (66/318) of those with a T-
score ≤ − 2.5 were not treated.
A diagnosis of OP also influenced prescribing in those
deemed not to be at increased risk of fracture (Fig. 1).
Treatment was only reported in 6% of those not at increased
risk, but this ranged from 2.0% in those without a diagnosis of
OP to 42% in those with a diagnosis. Regardless of risk of FF,
nearly all (96.1%) of those without an OP diagnosis did not
receive OP medication (Fig. 1).
The reasons for being classified as being at increased risk
of FF are shown in Table 3. Of the 2077 women, 1200
(57.8%) qualified because they had experienced a prior frac-
ture. Of these, 1020 (85%) also exceeded the country-specific
FRAX threshold. A further 794 women were classified be-
cause their fracture probability exceeded the country-specific
FRAX threshold. The fracture risk of these patients was sim-
ilar to that observed in patients reporting a history of prior
fracture (Table 3). The fracture risk in those identified by
FRAX probability, whether alone or in combination with oth-
er criteria, was consistently higher than in those identified
without considering fracture probability. Only a small propor-
tion of patients met the definition for increased risk of FF by
T-score only (4.0%), reflecting the fact that BMD results were
only available in a small subset (24.9%) of the cohort. Of the
944 women with BMD recorded, 318 (33.7%) had a T-score
of ≤ − 2.5 at one of the 3 skeletal sites.
OP medication use
Overall, 626 patients (16.5%) had received or were receiving
OP medication, of whom 422 (67.4%) were currently using
OP medication and 204 (32.6%) had used it previously. The
most common OP medications used (Table 4) were oral BPs
(67.4%), denosumab (29.9%), and parenteral BPs (13.6%).
Patients with a history of spine fracture received an OP med-
ication more frequently than those with a history of hip frac-
ture (57.9% vs. 35.9%).
Oral BP constituted the majority of first-line OP medica-
tion (58.3%), followed by denosumab (28.3%) and parenteral
BP (8.4%). Denosumab was the most common second-line
OP medication (76.3%), followed by parenteral BP (10.0%)
and oral BP (7.5%).
Most (90.1%) OP medication users also received vitamin
D/calcium supplements. 30.5% of the patients overall re-
ceived vitamin D/calcium supplements alone (data not
shown).
Subgroup and sensitivity analyses
Increasing or decreasing the FRAX-based thresholds (as de-
scribed in the “Methods” section) only had a relatively small
Fig. 1 Patient flowchart (adapted from [12]). FF, fragility fracture; OP, osteoporosis. aUnknown OP diagnosis in 35 patients at increased risk of fracture
(1 treated, 34 untreated). bUnknown OP diagnosis in 26 patients not at increased risk of fracture (all untreated)
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effect on the proportion of the population identified at in-
creased risk. The proportion ranged from 52.3 to 57.7% for
the higher and lower thresholds, respectively (Online
Resource Table S2). This also had little impact on the esti-
mates of the treatment gap, with values being 74.0% and
75.7%, respectively (Online Resource Table S3).
Since there were differences in speed of recruitment across
centers, we compared the baseline characteristics of the first
50% of patients enrolled to the next 50% to see if biases had
gradually influenced the types of patients recruited.
Reassuringly, the characteristics were remarkably similar in-
cluding age, reasons for consultation, and OP diagnosis
(Online Resource Table S4), as well as for comorbidities
(Online Resource Table S5) and fracture history (Online
Resource Table S6).
Discussion
Our study found a large treatment gap for women aged ≥ 70
years at increased risk of FF who were in routine primary care
across 8 countries in Europe. Overall, just over half were
found to be at increased risk of FF, of whom three-quarters
were not receiving any OP medication. Even among patients
with prior spine or hip fractures, the treatment gap was high,
with 42% and 64%, respectively, not receiving OP treatment.
While the treatment gap varied, it was above 50% in all 8
countries. The treatment gap in patients with prior hip fracture
was lowest in Ireland (43%), Belgium (46%), and the UK
(55%), and highest in Switzerland (88%) and Germany
(94%). We observed that a diagnosis of OP has a substantial
impact; the treatment gap was much smaller in those with an
OP diagnosis (30.9% vs. 74.6% in the overall population) and
much larger in those without an OP diagnosis (94.1%). The
treatment gap therefore appears to be largely related to a gap in
diagnosis or awareness.
The large treatment gap reported here is consistent with
previous studies. For example, treatment gaps of 55–68%
have been reported for Europe using different methodologies
[1, 3, 13]. Even in the presence of a prior fracture, treatment
rates have been reported to be low for secondary prevention
[2] and have also been shown to be declining over time [3].
Table 2 Characteristics, OP diagnosis, comorbidities, clinical risk factors, and 10-year fracture probability in patients with increased risk of fragility
fracture vs. those without increased risk
Parameter With increased risk of fragility fracturea,b
(N = 2077)
Without increased risk of fragility fracturea,b
(N = 1721)
Age, median (Q1, Q3), years 80.0 (75.0, 84.0) 75.0 (72.0, 78.0)
BMI, median (Q1, Q3), kg/m2 25.7 (22.9, 29.3) 28.6 (25.5, 32.1)
Known OP diagnosis, n (%) 641 (30.9) 163 (9.5)
At least one comorbidity, n (%) 1854 (89.3) 1507 (87.6)
Clinical risk factors for fragility fracture, n (%)
Previous fracture 1200 (57.8) 0 (0.0)
Hip 145 (7.0) 0 (0.0)
Spine 178 (8.6) 0 (0.0)
Wrist 435 (20.1) 0 (0.0)
Other (except skull, finger, and toe fractures) 634 (30.5) 0 (0.0)
Parental hip fracture 302 (14.5) 64 (3.7)
Current smoker 132 (6.4) 99 (5.8)
Glucocorticoid use 157 (7.6) 19 (1.1)
Rheumatoid arthritis 130 (6.2) 21 (1.2)
Alcohol (≥ 3 units per day) 32 (1.5) 18 (1.0)
Femoral neck T-score, median (Q1, Q3) [n] − 1.8 (− 2.5, − 1.1) [518] − 1.0 (− 1.7, − 0.4) [209]
10-year fracture probability without BMD, median (Q1, Q3), %
Hip fracture 11.2 (7.6, 16.2) 4.1 (2.8, 6.2)
Major osteoporotic fracture 22.8 (18.0, 29.6) 11.5 (8.9, 14.7)
BMD, bone mineral density; BMI, body mass index; FF, fragility fracture; OP, osteoporosis
a A patient will be considered to be at increased risk of fragility fracture if ≥ 1 of the 3 following criteria are met: (1) had a history of fracture; (2) 10-year
probability of hip fracture without BMD > country-specific threshold and 10-year probability of major osteoporotic fracture without BMD > country-
specific threshold; (3) BMD T-score ≤ − 2.5 for any of lumbar spine/total hip/femoral neck
bNumber of patients enrolled in full analysis set. Percentages based on total number of patients in respective increased risk of fragility fracture category
using the base definition
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Across the EU, less than 20% of patients with FFs were re-
ported to receive treatment within the year following fracture
[1]. This treatment gap has also been reported in the elderly,
for whom the consequences of untreated OP are more severe.
Treatment gap was between 48 and 68% in Swedish women
aged over 70, with as few as 10% of elderly women with FFs
receiving any OP therapy [11]. Wide intercountry variability
in treatment uptake in women with higher risk of osteoporotic
fractures has also been reported in other studies [1, 3], and
could be due to different availability and reimbursement of
medications and differences in fracture risk. Fracture registries
may play an important role in improving access to treatment:
Ireland and the UK have national hip fracture registries and
had a relatively low treatment gap compared with other
countries. In all of these countries, treatment guidelines sug-
gest a case-finding approach for patient identification, but
there is variation in terms of which risk factors are acknowl-
edged, how fracture risk should be assessed, how BMD mea-
surements should be used, and the thresholds for treatment
initiation. Notwithstanding the wide availability of national
guidelines, it is clear that their recommendations are not al-
ways followed.
We observed that a diagnosis of OP has a substantial im-
pact on the treatment gap; in women at high risk, the gap was
much smaller in those with an OP diagnosis than in those
without (30.9% vs. 94.1%, respectively). A similarly reduced
treatment gap in those with a diagnosis of OP was reported in
the GLOW study [13]. A diagnosis of OP was therefore found
Table 3 Proportion of patients at increased risk of fragility fracture and 10-year fracture probability, according to fracture risk criteria
Parameter n (%) 10-year fracture probability without BMD, median (Q1, Q3), %
Hip fracture Major osteoporotic fracture
Number of patients with increased risk of fragility fracture 2077 (100.0) 7.2 (4.1, 11.9) 16.6 (11.5, 23.9)
Meeting 1 of the 3 criteria
Prior fracture only 168 (8.1) 4.4 (3.3, 5.6) 16.2 (12.7, 17.9)
FRAX threshold only 733 (35.3) 11.5 (8.9, 15.8) 21.1 (17.6, 25.8)
T-score onlya 83 (4.0) 5.8 (4.1, 7.7) 13.6 (11.0, 16.5)
Meeting 2 of the 3 criteria
Prior fracture and FRAX threshold 858 (41.3) 12.3 (8.7, 17.4) 26.7 (21.9, 32.3)
Prior fracture and T-score 12 (0.6) 5.4 (4.0, 5.9) 17.7 (16.4, 18.8)
FRAX threshold and T-score 61 (2.9) 13.9 (11.8, 18.9) 23.2 (21.1, 27.6)
Meeting all 3 criteria 162 (7.8) 14.2 (10.7, 24.0) 30.6 (25.1, 39.1)
BMD, bone mineral density; FRAX, Fracture Risk Assessment Tool; Q, quartile
a BMD results were only available in subset (24.9%) of the cohort
A patient was considered to be at increased risk of fragility fracture if ≥ 1 of the 3 following criteria were met: (1) had a history of fracture; (2) 10-year
probability of hip fracture without BMD > country-specific threshold and 10-year probability of major osteoporotic fracture without BMD > country-
specific threshold; (3) BMD T-score ≤ − 2.5 for any of lumbar spine/total hip/femoral neck
Groups are mutually exclusive (i.e., patients are only counted once with respect to how they met the criteria)
Percentages based on number of patients enrolled who are at increased risk of fragility fracture using the base definition
Fig. 2 OP treatment gap for
overall patients and by OP
diagnosis (adapted from [12]). CI,
confidence interval; FF, fragility
fracture; OP, osteoporosis. N
represents the number of patients
at increased risk of fragility
fracture using the base definition.
Thirty-five patients had an un-
known diagnosis of OP
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to be a key factor in the decision to treat patients at increased
risk of fracture. It is unclear why approximately one-third of
patients with a diagnosis still remain untreated: physicians
may be managing multiple other competing conditions and
may consider vitamin D/calcium supplements sufficient to
reduce fracture risk, or patients may have declined treatment
because of confusion about the future risk of fracture com-
pared with the risk of adverse effects, or may have developed
side effects to one treatment and not transitioned to another.
Our data demonstrate that oral bisphosphonates are still
the most widely used agents, comprising 58% of first-line
OP medication (58.3%) compared with 28% receiving
denosumab, and only 8% accessing parenteral bisphos-
phonate therapy. The vast majority of patients on
second-l ine therapy received non-oral treatment
(denosumab, 76%; parenteral BP, 10%), a pattern that is
consistent with recommendations in key European guide-
lines [9, 14–16].
This study has a number of strengths as well as limitations.
Care was taken during the study design and implementation to
reduce bias and optimize the generalizability of the results
within the participating countries. For example, site selection
and assessment was conducted by a third party, to avoid in-
clusion of sites with an existing relationship with the sponsor
and potentially having a particular interest in OP. The preva-
lence of risk factors and comorbidities is consistent with other
studies [17–19], indicating that the current study population is
representative of the primary care population. Furthermore,
the consistency of patient characteristics between those re-
cruited early to the study and those recruited later indicates
that the selection criteria were not altered to fulfill enrollment
targets. Our findings are consistent with a recent study in older
Swedish women that showed a treatment gap of 78% in those
eligible for treatment according to national guidelines [20].
Although there appears to be a clear link between osteoporosis
diagnosis and the treatment gap, the study was not designed to
establish causality for factors associated with lack of treat-
ment. We cannot exclude that a treatment decision by a GP
may affect whether they enter an osteoporosis diagnosis into
the medical record. Notably, the treatment gap was lowest in
the subgroup of patients with a T-score ≤ − 2.5 (21%), a
finding that suggests that treatment followed the diagnosis at
least in this subset of patients.
Taken together, our study and earlier studies suggest no
improvement in treatment rates over the last 10 years. The
increase in the treatment gap could be attributed to several
factors such as misconceptions about OP, lack of perceived
benefits of therapy, concern about side effects and medication
costs, lack of motivation, and lack of patient education [21].
Importantly, inadequate or incorrect information in the media
related to OP and its treatment are also associated with a low
awareness of the disease and, subsequently, low treatment
rates [22]. It is likely that novel strategies will be needed to
narrow the treatment gap, particularly in older women.
Greater awareness and ease of access to fracture risk assess-
ment and treatment are likely to play a part; for example, the
establishment of fracture liaison services in primary or sec-
ondary care settings increases BMD uptake and treatment ex-
posure and is associated with reductions in fracture risk [23].
The application of fracture risk assessment in primary care and
community settings was the focus of three recent randomized
controlled trials of screening using the FRAX tool [17, 24,
25]. A meta-analysis of the three studies [26] showed a statis-
tically significant reduction of major osteoporotic fractures
(hazard ratio [HR] = 0.91; 95% CI = 0.84–0.98) and hip frac-
tures (HR = 0.80; 95% CI = 0.71–0.91). The number needed
to be treated to prevent one fracture was 25–28 patients.
Educational and information technology–based solutions that
could further facilitate fracture risk assessment in primary care
could therefore be a critical step; it is of interest that there is a
Table 4 OP medication use in the overall population
OP medication type, n (%) Overall (N = 3798) Fracture history OP medication use (n =
626)
Number of prior lines of treatment in
current op medication users (n = 422)
Hip (n = 145) Spine (n = 178) Current Previous 0 1 2 or more
Any treatmenta 626 (16.5%) 52 (35.9%) 103 (57.9%) 422 (67.4%) 204 (32.6%) 321 (76.1%) 80 (19.0%) 21 (5.0%)
Denosumabb 187 (29.9) 19 (36.5) 48 (46.6) 174 (41.2) 13 (6.4) 91 (28.3) 61 (76.3) 18 (85.7)
Oral BPb 422 (67.4) 32 (61.5) 61 (59.2) 269 (63.7) 153 (75.0) 187 (58.3) 6 (7.5) 1 (4.8)
Parenteral BPb 85 (13.6) 10 (19.2) 18 (17.5) 57 (13.5) 28 (13.7) 27 (8.4) 8 (10.0) 1 (4.8)
PTHb 8 (1.3) 1 (1.9) 3 (2.9) 4 (0.9) 4 (2.0) 1 (0.3) 1 (1.3) 1 (4.8)
SERMb 41 (6.5) 4 (7.7) 6 (5.8) 28 (6.6) 13 (6.4) 16 (5.0) 4 (5.0) 0 (0.0)
Strontiumb 40 (6.4) 4 (7.7) 0 (0.0) 21 (5.0) 19 (9.3) 4 (1.2) 1 (1.3) 0 (0.0)
BP, bisphosphonate; OP, osteoporosis; PTH, parathyroid hormone; RANKL, receptor activator of nuclear factor kappa-Β ligand; SERM, selective
estrogen receptor modulators
a Proportions are expressed as a percentage of the total patients in that category (n in the header)
b The proportion of patients with an individual OP treatment is expressed as a percentage of patients with any treatment in that column
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negative correlation between frequency of FRAX usage in the
8 countries studied (derived from [27] and the observed treat-
ment gap (r = − 0.74, data not shown)), though this is not
evidence of causation.
In conclusion, our study provides insight into the treatment
gap and treatment practices in women ≥ 70 years of age in the
primary care setting in Europe. Improved identification and
assessment of fracture risk by primary care physicians should
be a priority for medical bodies and policymakers, to enable
informed treatment decisions that target those at greatest risk
of fracture, and who are most likely to benefit from OP
medications.
Acknowledgments Medical writing support was provided by Deepali
Mittal, an employee of Bridge Medical Consulting Ltd, and funded by
Amgen.
Funding information This study was sponsored by Amgen.
Compliance with ethical standards
The study has been approved by the appropriate institutional and/or na-
tional research ethics committee and has been performed in accordance
with the ethical standards as laid down in the 1964 Declaration of
Helsinki and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants includ-
ed in the study.
Conflicts of interest Eugene McCloskey: grants/research support from
ActiveSignal, Amgen, AR UK, AstraZeneca, Consilient Healthcare,
GSK, Hologic, I3 Innovus, Internis, IOF, Lilly, Medtronic, Merck,
MRC, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus,
Tethys, UCB, Unilever, and Warner Chilcott; consultant for
ActiveSignal, Amgen, Consilient Healthcare, Fresenius Kabi, GSK,
Synexus, and UCB; speaking fees from Agnovos, Amgen,
AstraZeneca, Consilient Healthcare, GSK, Hologic, Internis, Lilly,
Pfizer, Roche, Servier, and UCB. Bernard Cortet has received fees for
occasional interventions as an expert or speaker from Alexion, Amgen,
Expanscience, Ferring, Lilly, Medtronic, MSD, Mylan, Novartis, Roche
Diagnostics, and UCB. E. Czerwinski: traveling grant from Amgen.
Kerry Palmer, Robert Stad, James O’Kelly: Amgen employment and
stock ownership. Socrates Papapoulos: consulting/speaking fees from
Amgen, Axsome, Gador, Radius Health, UCB. Peyman Hadji: grants/
research, consultancy, and lecture fees from Amgen, AstraZeneca, Dr.
Kade/Besins, Exeltis, Gedeon Richter, Hexal, Hologic, Lilly, Mylan,
Novartis, Pfizer, and UCB. Jeetandera Rathi, Stephane Heijmans, Mark
Blagden, Juraj Payer: no disclosures.
Open Access This article is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License, which permits
any non-commercial use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the
article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of
this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
References
1. StrömO, Borgström F, Kanis JA et al (2011) Osteoporosis: burden,
health care provision and opportunities in the EU. A report prepared
in collaboration with the International Osteoporosis Foundation
(IOF) and the European Federation of Pharmaceutical Industry
Associations (EFPIA). Arch Osteoporos 6:59–155
2. Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and man-
agement of patients at increased risk of osteoporotic fracture: out-
comes of an ESCEO expert consensus meeting. Osteoporos Int 28:
2023–2034
3. Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in
the European Union: medical management, epidemiology and
economic burden. A report prepared in collaboration with the
International Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations (EFPIA).
Arch Osteoporos 8:136
4. Compston JE, McClung MR, Leslie WD (2019) Osteoporosis.
Lancet 393:364–376
5. Chenot R, Scheidt-Nave C, Gabler S, Kochen MM, Himmel W
(2007) German primary care doctors’ awareness of osteoporosis
and knowledge of national guidelines. Exp Clin Endocrinol
Diabetes 115:584–589
6. Lespessailles E, Cotté F-E, Roux C, Fardellone P, Mercier F,
Gaudin A-F (2009) Prevalence and features of osteoporosis in the
French general population: the Instant study. Joint Bone Spine 76:
394e400
7. Sahota O, Worley A, Hosking J (2000) An audit of current clinical
practice in the management of osteoporosis in Nottingham. Journal
of Public Health Medicine 22:466–472
8. Judge A, Javaid MK, Leal J, et al (2016) Chapter 7: Primary care
and hospital care costs for hip fracture patients. In: Models of care
for the delivery of secondary fracture prevention after hip fracture: a
health service cost, clinical outcomes and cost-effectiveness study
within a region of England. NIHR Journals Library, Southampton,
UK. Health Services and Delivery Research;4.28. https://www.
ncbi.nlm.nih.gov/books/NBK385602/. Accessed Sept 20, 2019
9. Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline
for the prevention and treatment of osteoporosis. Arch Osteoporos
12:43. https://doi.org/10.1007/s11657-017-0324-5 Accessed 17
Sept 2019
10. Marsh D, Åkesson K, Beaton DE (2011) Coordinator-based sys-
tems for secondary prevention in fragility fracture patients.
Osteoporos Int 22:2051–2065
11. Kanis JA, Svedbom A, Harvey N et al (2014) The osteoporosis
treatment gap. J Bone Miner Res 29:1926–1928
12. McCloskey E, Rathi J, Heijmans S et al (2019) Osteoporosis (OP)
diagnosis and treatment of women aged ≥70 years in primary care:
results from a large European cross-sectional study. World
Congress on Osteoporosis, Osteoarthritis and Musculoskeletal
Diseases, Paris, France, April 4–7, (poster P997)
13. Díez-Pérez A, Hooven FH, Adachi JD et al (2011) Regional differ-
ences in treatment for osteoporosis. The Global Longitudinal Study
of Osteoporosis in Women (GLOW). Bone 49:493–498
14. Dachverband Osteologie. DVO-LEITLINIE 2017 zur Prophylaxe,
Diagnostik und Therapie der Osteoporose bei postmenopausalen
Frauen und bei Männern (German). https://www.dv-osteologie.
o r g / up l oad s /Le i t l i n i e%202017 /DVO%20Le i t l i n i e_
Kitteltaschenversion_gesamt.pdf. Accessed 13 Mar 2020.
15. Briot K, Roux C, Thomas T, Blain H et al (2018) 2018 update of
French recommendations on the management of postmenopausal
osteoporosis. Joint Bone Spine 85:519–530
258 Osteoporos Int (2021) 32:251–259
16. Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for
the diagnosis and management of osteoporosis in postmenopausal
women. Osteoporosis Int 30:3–44
17. Shepstone L, Lenaghan E, Cooper C et al (2018) for SCOOP
Study Team. Screening in the community to reduce fractures in
older women (SCOOP): a randomised controlled trial. Lancet
391:741–747
18. Dennison EM, Compston JE, Flahive J et al (2012) Effect of co-
morbidities on fracture risk: findings from the Global Longitudinal
Study of Osteoporosis in Women (GLOW). Bone 50:1288–1293
19. Raherison C, Girodet P-O (2009) Epidemiology of COPD. Eur
Respir Rev 18:213–221
20. Lorentzon M, Nilsson AG, Johansson H, Kanis JA, Mellström D,
Sundh D (2019) Extensive undertreatment of osteoporosis in older
Swedish women. Osteoporosis International 30:1297–1305
21. HiligsmannM, Cornelissen D, Vrijens B et al (2019) Determinants,
consequences and potential solutions to poor adherence to anti-
osteoporosis treatment: results of an expert group meeting orga-
nized by the European Society for Clinical and Economic Aspects
of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) and the International Osteoporosis Foundation (IOF).
Osteoporos Int 30:2155–2165
22. Cipriani C, Pepe J, Minisola S, Lewiecki EM (2018) Adverse ef-
fects ofmedia reports on the treatment of osteoporosis. J Endocrinol
Invest 41:1359–1364
23. Wuab CH, Tuc ST, Chang YF et al (2018) Fracture liaison services
improve outcomes of patients with osteoporosis-related fractures: a
systematic literature review and meta-analysis. Bone 111:92–110
24. Rubin KH, Rothmann MJ, Holmberg T et al (2018) Effectiveness
of a two-step population-based osteoporosis screening program
using FRAX: the randomized Risk-stratified Osteoporosis
Strategy Evaluation (ROSE) study. Osteoporos Int 29:567–578
25. Merlijn T, Swart KM, van Schoor NM et al (2019) The effect of a
screening and treatment program for the prevention of fractures in
older women: a randomized pragmatic trial. J Bone Miner Res 34:
1993–2000
26. Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders
PJM (2020) Fracture prevention by screening for high fracture risk:
a systematic review and meta-analysis. Osteoporos Int 31:251–257
27. Chotiyarnwong P, Harvey NC, Johansson H et al (2019) Temporal
changes in access to FRAX(R) in Thailand between 2010 and 2018.
Arch Osteoporos 14:66
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
259Osteoporos Int (2021) 32:251–259
